ClinicalTrials.gg
RecruitingNCT06294405Updated Mar 5, 2024

Intraocular Lens Implant Registry Study

An observational study in Intraocular Lens Complication, Intraocular Lens Rotation and Intraocular Lens Associated Postoperative Inflammation, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by University Hospital Augsburg · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cataract with a site in Germany — 8 open to participants now, 11 under way, none of them phase 3. Cataract · Germany.

Planned enrollment
2nd of 11
500 · median 242
Started
2024
with 1 other
Observational
11 of 61
1 open now
Primary completion
2029-02
later than 10 of 10 live
Registered
55th of 61
by date

Among the 61 studies in Cataract with a site in Germany, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 55th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

8 of the 61 studies in Cataract with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cataract with a site in Germany, or all of them as a file.
02

Study summary

The goal of this registry study is to optimize the results with intraocular lens implants used in cataract surgery.

Read the detailed description

A variety of intraocular lens implants are available for patients undergoing cataract surgery and new technologies are continuously being developed in this field.

In the planned monocentric retro- and prospective clinical study, a database to optimize outcomes with modern intraocular lens implants will be established to further improve anatomical and functional outcomes.

Patients treated with an intraocular lens implant will be included. The retrospective evaluation of data includes data routinely collected prior to study inclusion (preoperative, intraoperative, postoperative up to the 1st study visit). Prospectively, refraction, visual acuity, examination findings, intraocular pressure and complications are recorded 1-6 months postoperatively. Depending on the type of IOL, results of further non-invasive measurements are also recorded. Optional follow-up visits with the aforementioned examinations are possible up to 10 years postoperatively.

03

Conditions studied

  • Intraocular Lens Complication
  • Intraocular Lens Rotation
  • Intraocular Lens Associated Postoperative Inflammation
  • Lens Opacities

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who receive an intraocular lens are offered to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Treatment with an intraocular lens implant 18 years of age or older Patient consent Full legal capacity

Exclusion criteria

Exclusion Criteria:

Dementia Pregnancy Breastfeeding

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • DeviceIntraocular lens Implantation

    Intraocular lenses are implanted during cataract surgery to replace the human crystalline lens.

06

What researchers measure

Primary outcomes

  1. Functional results with different Intraocular lenses

    Visual acuity with different intraocular lenses is determined.

    Time frame: 6 months

  2. Contrast sestivitiy with different Intraocular lenses

    Contrast sensitivity with different intraocular lenses is determined.

    Time frame: 6 months

  3. Anatomical results.

    Anatomical results with different intraocular lenses are determined.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2029, 59 months after the start.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's planned 59 months is above that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 5, 2024
StartActual
Feb 21, 2024
Primary completionEst.
Feb 14, 2029
CompletionEst.
Feb 14, 2029
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06294405
Lead sponsor
University Hospital Augsburg
Responsible party
Dr. med.Isabella Baur (Ophthalmologist, University Hospital Augsburg) — Principal investigator
First posted
Mar 5, 2024
Start date
Feb 21, 2024
Primary completion
Feb 14, 2029 (estimated)
Completion
Feb 14, 2029 (estimated)
Last update
Mar 5, 2024

Study contacts

Isabella Baur, MD
Contact
Isabella.Baur@uk-augsburg.de
0049821 400-2566

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion